A comprehensive view of amgen inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Amgen reports positive results from two long-term open label extension Phase 3 studies, which show injectable Repatha evolocumab safe and well-tolerated in adults with atherosclerotic cardiovascular disease; Repatha approved in US, Canada, EU, Japan
Published: April 29, 2022 by Amgen Inc.
Amgen reports Q1 GAAP net income down 10% year-over-year to US$1.5B as total revenue increases 6% from a year ago to US$6.2B; Repatha evolocumab, Prolia denosumab, EVENITY romosozumab-aqqg see double-digit volume increases in Q1
Published: April 28, 2022 by PR Newswire
Amgen breaks ground on new biomanufacturing facility in Holly Springs, North Carolina, expecting to launch operations by 2025; facility will support growing demand for medicines that treat serious illnesses such as cancer and heart disease
Published: March 14, 2022 by Amgen Inc.
Amgen presents NAVIGATOR Phase 3, PATHWAY Phase 2b trials data supporting Tezspire as 'first-in-class' severe asthma treatment; data show Tezspire reduces annualized asthma exacerbation rate in patients with severe asthma irrespective of biomarker levels
Published: March 03, 2022 by PharmaBiz
FDA approves BLA 125557 for Amgen’s Blincyto injection injectable containing blinatumomab 35 mcg in one formulation; drug is available by prescription only, with no therapeutic equivalents
Published: February 28, 2022 by US Food and Drug Administration News (CBNB Abstracts)

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count